Burleson & Company LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 81.3% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 3,242 shares of the medical research company’s stock after selling 14,130 shares during the period. Burleson & Company LLC’s holdings in Amgen were worth $807,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. OLD Mission Capital LLC acquired a new position in Amgen in the third quarter worth about $239,000. Sage Mountain Advisors LLC acquired a new position in Amgen in the fourth quarter worth about $365,000. Ironwood Wealth Management LLC. increased its holdings in shares of Amgen by 3,036.7% during the fourth quarter. Ironwood Wealth Management LLC. now owns 4,705 shares of the medical research company’s stock worth $1,082,000 after buying an additional 4,555 shares in the last quarter. Prime Capital Investment Advisors LLC increased its holdings in shares of Amgen by 43.1% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 1,139 shares of the medical research company’s stock worth $262,000 after buying an additional 343 shares in the last quarter. Finally, Mattern Capital Management LLC increased its holdings in shares of Amgen by 0.6% during the fourth quarter. Mattern Capital Management LLC now owns 21,454 shares of the medical research company’s stock worth $4,933,000 after buying an additional 126 shares in the last quarter. 75.31% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:AMGN traded up $4.59 during midday trading on Thursday, reaching $244.11. 48,644 shares of the company were exchanged, compared to its average volume of 2,709,228. Amgen Inc. has a fifty-two week low of $210.28 and a fifty-two week high of $276.69. The company has a debt-to-equity ratio of 3.34, a quick ratio of 1.34 and a current ratio of 1.66. The stock’s fifty day moving average price is $247.33. The firm has a market cap of $140.25 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 1.73 and a beta of 0.72.
In other Amgen news, SVP Nancy A. Grygiel sold 2,500 shares of Amgen stock in a transaction on Tuesday, May 11th. The shares were sold at an average price of $252.51, for a total value of $631,275.00. Following the sale, the senior vice president now directly owns 14,961 shares in the company, valued at approximately $3,777,802.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director R Sanders Williams sold 250 shares of Amgen stock in a transaction on Friday, May 7th. The shares were sold at an average price of $251.78, for a total transaction of $62,945.00. Following the completion of the sale, the director now owns 4,409 shares in the company, valued at $1,110,098.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,750 shares of company stock worth $1,194,790. 0.36% of the stock is currently owned by company insiders.
AMGN has been the subject of several recent analyst reports. Robert W. Baird reaffirmed a “sell” rating on shares of Amgen in a report on Thursday, April 29th. Royal Bank of Canada dropped their price objective on shares of Amgen from $220.00 to $217.00 and set a “sector perform” rating for the company in a report on Wednesday, April 28th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $290.00 price objective on shares of Amgen in a report on Wednesday, April 28th. Barclays dropped their price objective on shares of Amgen from $242.00 to $230.00 and set an “equal weight” rating for the company in a report on Friday, March 5th. Finally, BMO Capital Markets increased their price target on shares of Amgen from $296.00 to $301.00 and gave the company an “outperform” rating in a research note on Monday, May 31st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. Amgen has a consensus rating of “Hold” and a consensus target price of $256.81.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Read More: What is a SEC Filing?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.